Azitra Q2 FY26 net loss widens to $3.3 million

Reuters2026/08/12 20:56

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Azitra posted a net loss of USD 3.3 million for the quarter ended June 30, 2026, widening from USD 2.9 million a year earlier.
G&A expenses climbed to USD 2.1 million from USD 1.5 million, while R&D expenses were flat at USD 1.4 million.
Cash and cash equivalents totaled USD 6.7 million as of June 30, 2026.
Reported first preclinical ATR-COSF data showing repeat-dose delivery and anti-wrinkle activity; human cosmetic application study planned to start in Q3 2026.
ATR-04 Phase 1/2 trial continued enrolling; topline data from the first cohort expected in Q4 2026, while ATR-12 enrollment is set to pause.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Azitra Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001701478-26-000039), on August 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Azitra Q2 FY26 net loss widens to $3.3 million

You may also like

Crypto prices